Insilico Medicine (HKEX: 03696) is a publicly traded Aging Drug Discovery company founded in 2014 and based in Hong Kong, Hong Kong.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Dec 30, 2025 | IPO (HKEX: 2179) | $293M | $1.7B | Tencent, Eli Lilly |
| Mar 14, 2025 | Series E | $110M | — |
| Value Partners Group |
| Jun 8, 2022 | Series D | $60M | — | Warburg Pincus |

Insilico Medicine open-sources Longevity Grok, a free multi-agent system built with David Sinclair that files testable biomarker predictions and scores its own calibration.
Insilico Medicine open-sources Longevity Grok, a multi-agent personal longevity AI built with David Sinclair for Grok Bot users.
Insilico Medicine reports first-in-human Phase 1 data for ISM6331 with a 40% ORR at 130 mg in five evaluable mesothelioma patients, and an 18.2% ORR overall across 30–130 mg.
Pharma.AI is Insilico Medicine's end-to-end generative-AI drug discovery platform, spanning target identification (PandaOmics), generative chemistry for novel molecule design (Chemistry42), and clinical-trial outcome prediction (inClinico). The platform connects biology, chemistry, and clinical data to nominate disease targets and design drug candidates faster and at lower cost than conventional methods. It underpins Insilico's internal pipeline of clinical- and preclinical-stage programs and is also offered to pharmaceutical partners, and is paired with an automated, robotics-driven laboratory for experimental validation.
Insilico advances a pipeline of clinical- and preclinical-stage drug candidates discovered and designed using its generative-AI platform, with its lead programs aimed at fibrosis, oncology, and other age- and disease-related conditions. Several candidates have entered clinical trials, validating the AI-first discovery approach. Proceeds from the company's 2025 Hong Kong IPO are earmarked largely for advancing these clinical-stage candidates and for expanding early-stage discovery, new generative-AI models, and its automated laboratory.